Investor Relations

Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at NKF 2015 Spring Clinical Meetings more »

OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources more »

OPKO Lab Receives Accreditation From College of American Pathologists more »

Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney Disease to be Presented at ENDO 2015 Conference more »

Conferences & Events

Upcoming Events
Details on upcoming events are not yet available.

Archived Events
Mar 2, 2015
8:30 AM
OPKO Fourth Quarter and Full Year 2014 Financial Results
Webcast Listen to webcast
Feb 25, 2015
2:35 PM
RBC Capital Markets' Healthcare Conference
Webcast Listen to webcast
PDF View Presentation  1.1 MB